Last updated: February 15, 2026
Product Overview
NDC 50242-0041 is a formulation of Ertugliflozin, marketed under the brand Steglatro by Pfizer. It is a sodium-glucose cotransporter-2 (SGLT2) inhibitor used for type 2 diabetes management, often prescribed with diet and exercise.
Market Size and Demand
The global type 2 diabetes market exceeded $100 billion in 2022, with SGLT2 inhibitors accounting for approximately 35% ($35 billion). Ertugliflozin's share within this segment is estimated at 4-6%, reflecting its relatively recent entry (approval in 2017).
Key factors influencing demand:
- Rising prevalence of type 2 diabetes (approaching 540 million cases worldwide in 2022, per IDF)
- Growing adoption of SGLT2 inhibitors for cardiovascular and renal benefits.
- Increased prescribing according to clinical guidelines that recommend SGLT2 inhibitors early after diagnosis or failure of metformin alone.
Market Competition
Ertugliflozin competes within a cluster that includes empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana). Among these, Jardiance led in 2022 sales with approximately $4.4 billion globally, followed by Farxiga with ~$4 billion. Ertugliflozin's sales stood at around $300-400 million, reflecting its status as a later entrant.
Pricing Environment
U.S. wholesale acquisition cost (WAC) for a 30-tablet supply (10 mg strength) is roughly $480–$520. Pharmacy benefit manager (PBM) negotiated prices tend lower, averaging $300–$400 per month per patient. Pricing variability depends on formulary status, insurance coverage, and negotiated rebates.
Price Projections (Next 5 Years)
| Year |
Estimated U.S. WAC for 30 tablets (10 mg) |
Estimated Sales (U.S.) |
Market Share |
Comments |
| 2023 |
$500 |
$350 million |
3-4% |
Stable demand; generic entry unlikely soon. |
| 2024 |
$490 |
$400 million |
4-5% |
Slight price decrease; increased market penetration. |
| 2025 |
$470 |
$450 million |
5-6% |
Growth driven by prescribing trends. |
| 2026 |
$460 |
$500 million |
6-7% |
Authorization of additional indications possible. |
| 2027 |
$450 |
$550 million |
6-8% |
Market expansion in cardiovascular and renal uses. |
Note: International pricing varies significantly, often five to ten times lower than U.S. levels, dependent on country reimbursement schemes.
Factors Affecting Future Prices
- Generic Competition: patent expiry estimated around 2028-2029.
- Reimbursement Policies: Payers may negotiate substantial rebates, lowering net prices.
- Market Penetration: Stronger formulary placement and physician adoption could sustain higher prices.
- Regulatory Changes: New approvals for expanded indications (e.g., heart failure, CKD) could influence demand and pricing strategies.
Regulatory and Patent Status
Ertugliflozin's patent protection extends to approximately 2028, with some formulations potentially facing generic competition shortly thereafter. Patent litigation and settlement terms can affect timing.
Supply Chain and Manufacturing
Pharmaceutical manufacturing costs are declining with advanced synthesis and supply chain optimization, marginally impacting pricing. Volume-based discounts are common at the wholesale level.
Summary of Competitive Position
- Ertugliflozin maintains a niche driven by its safety profile and secondary benefits.
- It commands a premium in formulary preferences due to evidence of cardiovascular benefits.
- Price positioning remains competitive, with room for strategic discounts to increase penetration.
Key Takeaways
- The global SGLT2 inhibitor market exceeds $35 billion, with steady growth forecasted.
- Ertugliflozin's sales are expected to grow modestly through 2027, reaching approximately $550 million annually in the U.S.
- Pricing remains stable but is subject to discounting, competition, and patent expiration.
- Market expansion hinges on regulatory approvals for additional indications, increased physician adoption, and favorable reimbursement policies.
- Potential generic entry around 2028-2029 could reduce prices significantly, impacting revenue projections.
FAQs
-
When is patent expiry for Ertugliflozin?
Estimated around 2028, barring patent challenges or extensions.
-
How does Ertugliflozin compare to other SGLT2 inhibitors in efficacy?
Similar blood glucose reduction; cardiovascular and renal benefits are comparable but vary by patient profile and clinical data.
-
What are the main factors influencing its market share?
Prescribing guidelines, formulary placements, patent protection, and clinical trial outcomes.
-
Are there any upcoming regulatory approvals?
Not currently; ongoing trials for expanded indications like heart failure could influence future approvals.
-
How do international prices differ?
Significantly lower; for example, prices in Europe or emerging markets are typically 50-90% lower than in the U.S.
Sources
[1] IQVIA, "Pharmaceutical Market Reports," 2022
[2] International Diabetes Federation, "IDF Diabetes Atlas," 2022
[3] Pfizer, "Ertugliflozin (Steglatro) Product Label," 2023
[4] Evaluate Pharma, "Global Revenue Forecasts," 2023
